Cheigh J S, Suthanthiran M, Kaplan M, Evelyn M, Riggio R R, Fotino M, Schechter N, Wolf C F, Stubenbord W T, Stenzel K H
Transplantation. 1984 Nov;38(5):501-6. doi: 10.1097/00007890-198411000-00012.
We developed a new and simplified donor-specific blood transfusion (DSBT) protocol for prospective kidney transplant recipients from one-haplotype-mismatched related donors. Prospective kidney donors gave 450 ml of blood in a quad-pack unit, and the blood was stored in a blood bank. Twenty-five patients were transfused with 100 ml of the respective donor's whole blood at 1, 8, and 15 days after its storage. After DSBT, only three (12%) developed donor-specific lymphocytotoxic antibodies. Following DSBT, donor-specific mixed lymphocyte culture (MLC) was significantly suppressed, without any accelerated (secondary-type) response in early MLC. In addition, sera obtained after DSBT also suppressed donor-specific MLC significantly. Sixteen recipients subsequently received a kidney transplant from the donor, and all had functioning grafts at three months, but one lost the graft thereafter (graft survival rate: 94% at 12 months). This study indicates that (1) 100 ml of stored whole-blood DSBT three times at weekly intervals is a practical, less immunizing, and effective approach to enhance graft survival in recipients of a one-haplotype-mismatched graft; and (2) immune consequences of DSBT include induction of donor-specific cellular and humoral adaptive responses that might be conducive to successful graft outcome.
我们为单倍型不匹配的亲属供体的前瞻性肾移植受者制定了一种新的简化的供体特异性输血(DSBT)方案。前瞻性肾供体以四联袋单位捐献450毫升血液,并将血液储存在血库中。25名患者在血液储存后的第1天、第8天和第15天接受了100毫升各自供体的全血输血。DSBT后,只有3名患者(12%)产生了供体特异性淋巴细胞毒性抗体。DSBT后,供体特异性混合淋巴细胞培养(MLC)受到显著抑制,早期MLC中没有任何加速(二次型)反应。此外,DSBT后获得的血清也显著抑制了供体特异性MLC。16名受者随后接受了来自供体的肾移植,所有患者在3个月时移植肾均有功能,但其中1名患者此后失去了移植肾(12个月时移植肾存活率:94%)。本研究表明:(1)每周3次、每次100毫升储存全血的DSBT是一种切实可行、免疫原性较低且有效的方法,可提高单倍型不匹配移植受者的移植肾存活率;(2)DSBT的免疫后果包括诱导供体特异性细胞和体液适应性反应,这可能有助于移植成功。